Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

OGT Launches Pre-Implantation Genetic Screening Array

Published: Wednesday, June 05, 2013
Last Updated: Wednesday, June 05, 2013
Bookmark and Share
CytoSure Single Cell Aneuploidy array detects abnormalities across all chromosomes.

Oxford Gene Technology (OGT) has announced the launch of a new pre-implantation genetic screening (PGS) array aimed at improving the chances of successful in-vitro fertilization (IVF).

The array detects chromosome number abnormalities (aneuploidy) across all 24 human chromosomes using DNA amplified from a single cell from an early-stage embryo. This allows selection of an embryo with a normal chromosomal content.

The number of women receiving IVF has increased steadily, however the percentage of IVF treatments resulting in viable pregnancies is still comparatively low with chromosomal aneuploidy a leading genetic cause of unsuccessful IVF.

It has been reported that 75% of eggs in women over 37 and 23% of eggs in younger women are chromosomally abnormal.

OGT’s CytoSure™ Single Cell Aneuploidy array is the first commercially available oligonucleotide aCGH product designed specifically for PGS.

The array is sensitive enough to work with small amounts of amplified DNA from a single cell from an early-stage embryo. Unlike technologies such as fluorescence in situ hybridization (FISH), the array can detect aneuploidies across the whole genome.

The array allows eight samples to be run simultaneously, which is more than existing bacterial artificial chromosome (BAC) aneuploidy arrays, minimizing sample-to-sample variation by reducing technical noise.

The array is complemented by OGT’s CytoSure Interpret Software which analyses the data generated to produce simple, easy-to-use results.

The ability to clearly identify aneuploidy is vital to make a confident and informed decision as to the chromosomal content of an embryo.

The array has also been research-validated to investigate aneuploidies in first polar bodies, single blastomeres and trophectoderm biopsies.

Dr Mike Evans, CEO, OGT said, “With the launch of the CytoSure Single Cell Aneuploidy array we are moving into a new and valuable area both as a company and in the wider sense of seeking to improve reproductive health. The superior resolution, throughput and full chromosome coverage of our array allows improved identification of aneuploidy. We are hopeful that this new product will contribute significantly to helping potential parents maximize their chances of IVF success.”


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

OGT Appoints Dr Bob Holland as CMO
Company strengthens focus on cancer biomarkers.
Monday, October 21, 2013
OGT Supports Earlier Lupus Diagnosis
Superior sensitivity and specificity compared to current laboratory tests.
Friday, May 10, 2013
OGT to Host Company Showcase at BioTrinity 2012
Seminar to discuss company’s biomarker accelerator strategy for optimizing drug and diagnostic development.
Monday, April 23, 2012
OGT Signs Licensing Deal for Colorectal Cancer Biomarkers
OGT has entered into an exclusive licensing agreement with Inven2.
Thursday, February 23, 2012
OGT Releases New Whitepaper for Aiding Biomarker Discovery
The new document explores the need for biomarkers as indicators of disease, and discusses the vast potential of autoantibodies as markers of early disease development.
Tuesday, January 24, 2012
Oxford Gene Technology and Abcodia Form Partnership
Companies combine expertise to advance biomarkers for the early diagnosis of pancreatic cancer.
Tuesday, November 08, 2011
OGT Named by Agilent as the First High-Throughput Microarray Certified Service Provider
Certificate confirms OGT as the world’s leading choice for large-scale outsourced microarray studies.
Wednesday, March 03, 2010
Scientific News
Promising Class of New Cancer Drugs Cause Memory Loss in Mice
New findings from The Rockefeller University suggest that the original version of BET inhibitors causes molecular changes in mouse neurons, and can lead to memory loss in mice that receive it.
Electrical Control of Cancer Cells
Research led by scientists at The University of Texas Health Science Center at Houston (UTHealth) has revealed a new electrical mechanism that can control these switches.
Signature of Microbiomes Linked to Schizophrenia
Studying microbiomes in throat may help identify causes and treatments of brain disorder.
Inflammation Linked to Colon Cancer Metastasis
A new Arizona State University research study led by Biodesign Institute executive director Raymond DuBois has identified for the first time the details of how inflammation triggers colon cancer cells to spread to other organs, or metastasize.
Structural Discoveries Could Aid in Better Drug Design
Scientists have uncovered the structural details of how some proteins interact to turn two different signals into a single integrated output.
Determining the Age of Fingerprints
Watch the imprint of a tire track in soft mud, and it will slowly blur, the ridges of the pattern gradually flowing into the valleys. Researchers have tested the theory that a similar effect could be used to give forensic scientists a way to date fingerprints.
Genetic Overlapping in Multiple Autoimmune Diseases May Suggest Common Therapies
CHOP genomics expert leads analysis of genetic architecture, with eye on repurposing existing drugs.
Surprising Mechanism Behind Antibiotic-Resistant Bacteria Uncovered
Now, scientists at TSRI have discovered that the important human pathogen Staphylococcus aureus, develops resistance to this drug by “switching on” a previously uncharacterized set of genes.
Tissue Bank Pays Dividends for Brain Cancer Research
Checking what’s in the bank – the Brisbane Breast Bank, that is – has paid dividends for UQ cancer researchers.
Researchers Publish Landmark “Basket Study”
Researchers from Memorial Sloan Kettering Cancer Center (MSK) have announced results from the first published basket study, a new form of clinical trial design that explores responses to drugs based on the specific mutations in patients’ tumors rather than where their cancer originated.
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!